Prognostic significance of systemic immune-inflammation index in patients with intrahepatic cholangiocarcinoma undergoing hepatic resection

Table 2 Correlation between systemic immune-inflammation index and clinicopathological characteristics in derivation and validation cohort

Variables	Derivation			Validation
	SII ≤ 450	SII > 450	P value	SII ≤ 450	SII > 450	P value
Total patients	123	142		130	135
Age, yr	57.89 (9.5)	57.98 (11.3)	0.943	57.79 (10.7)	55.41 (10.9)	0.074
Male gender, n (%)	67 (54.5)	67 (47.2)	0.268	61 (46.9)	61 (45.2)	0.806
HBsAg, n (%)	45 (36.9)	35 (24.6)	0.033	39 (30.2)	34 (25.2)	0.413
Hepatolithiasis, n (%)	15 (12.2)	27 (19.0)	0.164	22 (16.9)	25 (18.5)	0.758
CA-199 < 22, n (%)	40 (33.1)	37 (27.2)	0.010	45 (34.9)	28 (21.2)	0.002
Platelet	139 (45)	214 (75)	< 0.001	141 (50)	213 (70)	< 0.001
Neutrophil	3.34 (1.0)	5.65 (2.5)	< 0.001	3.46 (1.3)	5.66 (1.9)	< 0.001
Lymphocyte	1.81 (1.7)	1.43 (0.5)	0.009	1.73 (0.5)	1.41 (0.5)	< 0.001
Tumor size, cm	5.2 (2.3)	6.5 (2.9)	< 0.001	5.40 (2.2)	6.36 (3.0)	0.007
Solitary tumor, n (%)	99 (80.5)	97 (68.3)	0.025	92 (70.8)	86 (63.0)	0.197
Well tumor differentiation, n (%)	7 (5.7)	4 (2.8)	0.357	8 (6.2)	3 (2.2)	0.110
Macrovascular invasion, n (%)	33 (26.8)	38 (26.8)	1.000	23 (17.7)	29 (21.5)	0.449
Microvascular invasion, n (%)	12 (9.8)	15 (10.6)	0.844	9 (6.9)	18 (13.3)	0.103
Node positive, n (%)	20 (16.3)	41 (28.9)	0.020	27 (20.8)	41 (30.4)	0.089
Perineural invasion, n (%)	19 (15.4)	19 (13.4)	0.732	22 (16.9)	20 (14.8)	0.745
TNM stage, n (%)			0.017			0.123
IA	22 (17.9)	11 (7.7)		16 (12.3)	14 (10.4)
IB	11 (8.9)	10 (7.0)		8 (6.2)	9 (6.7)
II	14 (11.4)	12 (8.5)		11 (8.5)	19 (14.1)
IIIA	56 (45.5)	66 (46.5)		68 (52.3)	52 (38.5)
IIIB	20 (16.3)	43 (30.3)		27 (20.8)	41 (30.4)

Age, platelet, neutrophil and lymphocyte were shown as mean (SD). M: Male; F: Female; CA-199: Carbohydrate antigen-199; TNM: Tumor-node-metastasis; SII: Systemic immune-inflammation index; HR: Hazard ratio; CI: Confidence interval.